Osimertinib(泰瑞沙)奥希替尼每次吃多少,Osimertinib(Osimertinib)推荐剂量为每日80mg，直至疾病进展或出现无法耐受的毒性。

Osimertinib (Trade name: Tagrisso) is a targeted therapy drug that is used in the treatment of non-small cell lung cancer (NSCLC). Specifically, it is prescribed for patients with advanced NSCLC that has certain mutations in the epidermal growth factor receptor (EGFR) gene. This medication has shown promising results in improving outcomes for patients with this specific type of lung cancer. The dosage of Osimertinib may vary depending on several factors, including the patient's overall health, weight, and specific EGFR mutation status. Here, we will provide accurate information regarding the recommended dosage of Osimertinib.

1. The Recommended Dosage of Osimertinib:

The recommended dosage of Osimertinib is 80 milligrams (mg) once daily, taken orally with or without food. It is important to follow the prescribed dosage instructions given by your healthcare provider. Do not alter the dosage without consulting your doctor.

2. Factors Influencing Dosage:

The dosage of Osimertinib may be adjusted based on individual factors such as weight, kidney function, liver function, and other ongoing health conditions. Your healthcare provider will determine the appropriate dosage for you after considering these factors.

3. Compliance with Treatment:

To ensure the effectiveness of Osimertinib, it is crucial to take the medication exactly as prescribed by your doctor. Missing doses or altering the dosage without medical guidance may reduce its efficacy. If you have any concerns or experience difficulties with the prescribed dosage, talk to your healthcare provider for further guidance.

4. Possible Side Effects and Monitoring:

While Osimertinib is generally well-tolerated, some patients may experience side effects. Common side effects include diarrhea, skin rash, dry skin, nail changes, fatigue, decreased appetite, and respiratory symptoms such as cough and shortness of breath. Your doctor will monitor you for any potential side effects and may adjust the dosage or provide supportive care if needed. It is important to communicate any side effects you may experience to your healthcare team.

In conclusion, the recommended dosage of Osimertinib (Tagrisso) for the treatment of advanced non-small cell lung cancer with specific EGFR mutations is 80mg once daily. Adhering to the prescribed dosage and closely monitoring for any side effects can help maximize the benefits of this targeted therapy. As always, it is essential to consult with your healthcare provider for personalized advice and guidance regarding your specific treatment plan.